Enter your keyword

Efficiently Creating Value with Innovative Science

Investors & News

Investor Overview
Press Releases
Stock Quote
SEC Filings
Events & Presentations
Investor Contacts
Alerts
Corporate Governance

Day High:
Day Low:
Volume:

4:14 PM EDT Mar 24, 2021

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Intra
3 mo.
6 mo.
1 yr.

Unsubscribe from all Mateon Therapeutics email alerts

Email Address

Leave this field blank

Shareholder Tools

Email Alerts

Email Alerts
Downloads

Downloads
Print

Print
Share

Share
Search

Search

Facebook
LinkedIn
Twitter
RSS

About Mateon

Mateon has three major business segments: 1) PointR- developer of vision grid/cluster computing/AI to support drug development. 2) Mateon/Oxigene- developer of Vascular Disrupting Agent (CA4P and Oxi4503). FDA granted CA4P rare pediatric designation for pediatric melanoma in 2020 and OXi4503 rare pediatric designation for pediatric ALL. 3) Oncotelic- developer of OT-101 - an antisense against TGF-beta- for the treatment of cancers. OT-101 completed phase 2 with good safety and efficacy against pancreatic cancer, glioblastoma, and melanoma. OT-101 also been granted rare pediatric designation against pediatric DIPG in 2019. OT-101 is also being deployed against COVID-19. OT-101 is in phase 2 clinical trial against COVID. We are also developing Artemisinin in phase 4 clinical trial against COVID. It is approved by India for symptoms frequently observed in COVID. It is being launch by end of 2020. Global launch will be soon after.

Links

Home
COVID-19
Pipeline
EdgePoint
About Us
Investors
Contact

Our Office

Mateon Corporate Headquarters

29397 Agoura Road, Suite 107
Agoura Hills, CA 91301
info@mateon.com
(650) 635-7000
(650) 635-7001